201. Ivacaftor-elexacaftor-tezacaftor and tacrolimus combination in cystic fibrosis.
- Author
-
Smith M, Ryan KJ, Gutierrez H, Sanchez LHG, Anderson JN, Acosta EP, Benner KW, and Guimbellot JS
- Subjects
- Adolescent, Chloride Channel Agonists therapeutic use, Drug Therapy, Combination, Female, Humans, Immunosuppressive Agents therapeutic use, Aminophenols therapeutic use, Benzodioxoles therapeutic use, Cystic Fibrosis drug therapy, Indoles therapeutic use, Liver Transplantation methods, Pyrazoles therapeutic use, Pyridines therapeutic use, Pyrrolidines therapeutic use, Quinolones therapeutic use, Tacrolimus therapeutic use
- Abstract
The CFTR modulator combination elexacaftor/tezacaftor/ivacaftor (ETI) is a genetic mutation-targeted treatment in cystic fibrosis that results in profound improvements in clinical outcomes. Each of the compounds are substrates of CYP3A4/5, the cytochrome P450 enzyme family for which tacrolimus is also a substrate. The use of these compounds in an individual with a solid organ transplant has not been previously studied and there is potential for a drug interaction. In this report, we describe a pediatric liver transplant recipient with clinical decline related to cystic fibrosis who improved substantially with ETI, without significant impact on the systemic exposure of either ETI or tacrolimus., Competing Interests: Declaration of Competing Interest All authors declare no conflicts of interest., (Copyright © 2021 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF